Lupin tops world pharma and all Indian sectors in S&P ESG rankings
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
Subscribe To Our Newsletter & Stay Updated